ALKS vs CRL: fair value comparison
Alkermes plc and Charles River Laboratories International, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, ALKS currently sits closer to the top of our ranking by discount to fair value. ALKS carries the stronger quality grade.
| ALKS | CRL | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $41.22 | $301.79 |
| 12-month range | $27.20–$55.22 | $149.93–$310.77 |
| Rank by discount to fair value | #91 of 108 Healthcare | #108 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ALKS fair value analysis · CRL fair value analysis